MedTrace Logo

The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia

NCT00206947 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-09-20

No results posted yet for this study

Summary

The present study will specify and delineate the separate components of cognitive deficits and examine the effects of adjunctive cholinergic augmentation on these cognitive deficits as well as psychopathology in schizophrenic patients treated with an antipsychotic compound with no aberrant binding affinity for the cholinergic receptor system. The hypothesis is that cholinergic augmentation using donepezil will improve cognitive deficits, sensory gating deficits, and psychopathology in schizophrenic patients treated with an atypical antipsychotic (ziprasidone).

Conditions

Interventions

DRUG

donepezil (5-10 mg/day)

Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment

DRUG

Placebo

Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • Birte Glenthoj

    lead OTHER

Principal Investigators

  • Birte Glenthoj, MD, DMSc. · Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychaitric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206947 on ClinicalTrials.gov